My retirem_老虎社区_美港股上老虎

2021-11-02

My retirement stock for the future 🚀

2 Best Biotech Stocks to Buy in November<blockquote>11 月最值得买入的 2 只生物技术股票</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":841072224,"tweetId":"841072224","gmtCreate":1635865742259,"gmtModify":1635866541326,"author":{"id":3567060979533928,"idStr":"3567060979533928","authorId":3567060979533928,"authorIdStr":"3567060979533928","name":"Reminiscent","avatar":"https://static.tigerbbs.com/756f10ded1f79212c0f44c111c0d9278","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>My retirement stock for the future 🚀&nbsp;</body></html>","htmlText":"<html><head></head><body>My retirement stock for the future 🚀&nbsp;</body></html>","text":"My retirement stock for the future 🚀","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/841072224","repostId":1135028228,"repostType":2,"repost":{"id":"1135028228","kind":"news","pubTimestamp":1635822901,"share":"https://www.laohunote.com/m/news/1135028228?lang=zh_CN&edition=full","pubTime":"2021-11-02 11:15","market":"us","language":"en","title":"2 Best Biotech Stocks to Buy in November<blockquote>11 月最值得买入的 2 只生物技术股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1135028228","media":"Motley Fool","summary":"Biotech stocks appear to be poised for a strong showing in November for a host of reasons. First and","content":"Biotech stocks appear to be poised for a strong showing in November for a host of reasons. First and foremost, the industry's biggest headwind this year -- drug pricing reform -- was conspicuously left out of the social spending bill recently released by the White House. Second, the latest earnings reports from top big pharma companies like&nbsp;Merck&nbsp;have been&nbsp;better than expectedso far. Lastly, scores of drugmakers are slated to release key clinical and regulatory updates this month.<blockquote>由于多种原因，生物技术股似乎有望在 11 月份出现强劲表现。首先也是最重要的是，该行业今年最大的阻力——药品定价改革——明显被排除在白宫最近发布的社会支出法案之外。其次，顶级大型制药公司的最新收益报告，例如默克到目前为止比预期要好。最后，数十家制药商将于本月发布关键的临床和监管更新。</blockquote> Which&nbsp;biotech stocks&nbsp;could be the belles of the ball in November?Bionano Genomics(NASDAQ:BNGO)and&nbsp;Ocugen(NASDAQ:OCGN)are two names that growth-oriented investors should definitely have on the radars this month. Here's why.<blockquote>哪些生物科技股可能是 11 月份的亮点？生物纳米基因组学（纳斯达克代码：BNGO）和奥库根（纳斯达克股票代码：OCGN）是成长型投资者本月绝对应该关注的两个名字。原因如下。</blockquote> Bionano Genomics: Time to buy this fallen angel<blockquote>Bionano Genomics：是时候购买这个堕落天使了</blockquote> Personalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.<blockquote>个性化医疗是生物技术研究的圣杯。尽管随着免疫疗法的出现，癌症治疗取得了许多突破，但该领域的临床成功通常以低至30%的缓解率为特征。研究人员认为，这些极低的应答率源于特定患者群体中核酸和整个染色体水平上的突变类型差异。实际上，癌症并不是一种铁板一块的疾病，因此不可能开发出一种放之四海而皆准的疗法。</blockquote> To boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.<blockquote>为了提高这些新型抗癌治疗的功效，研究人员需要在个体水平上准确了解恶性肿瘤的遗传结构。这就是像 Bionano Genomics 这样的公司发挥作用的地方。Bionano Genomicssportsa 基于非测序的光学测绘技术，称为 Saphyr 系统。Saphyr系统旨在快速表征极长的基因组DNA链。</blockquote> What's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.<blockquote>此外，该生物技术公司最近收购了领先的基因组数据分析软件公司 BioDiscovery。这项具有里程碑意义的收购可能会成为公司及其股东改变游戏规则的业务发展举措。简而言之，BioDiscovery 的 NXClinical 变异分析软件解决方案与 Saphyr 系统相结合，有可能加速光学基因组作图的普及。此外，这个潜在的一流平台最终可能会在未来几年内占据这个数十亿美元市场的巨大份额。</blockquote> Why should investors buy this stock in November? Bionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.<blockquote>为什么投资者应该在11月购买这只股票？Bionano 定于 11 月 4 日公布第三季度收益。虽然生物技术公司第三季度的收入数据不太可能引人注目，但投资者应该更多地了解这项关键收购的长期影响。因此，Bionano 遭受重创的股票在经历了八个月的低迷后可能最终开始显示出一些生命迹象。强调这一点的是，这家生物技术公司的股价目前相对于 52 周高点下跌了 67%。反过来，激进的投资者可能希望在即将发布的收益报告之前买入一些股票。</blockquote> Ocugen: An underappreciated COVID-19 vaccine stock<blockquote>Ocugen：被低估的 COVID-19 疫苗股票</blockquote> Thanks to its popularity onsocial media, Ocugen's shares have jumped by an astounding 547% so far this year. The biotech's appeal to the social media crowd isn't without reason, however. Ocugen's North American co-commercialization agreement with India's Bharat Biotech for the COVID-19 vaccine Covaxin is expected to lead to a monstrous rise in its top line in 2022 and beyond. Wall Street, in fact, thinks the vaccine's North American sales may top $400 million within the next two years.<blockquote>由于其在社交媒体上的受欢迎程度，Ocugen 的股价今年迄今已上涨了 547%，令人震惊。然而，生物技术对社交媒体人群的吸引力并非没有原因。Ocugen 与印度 Bharat Biotech 就 COVID-19 疫苗科瓦克辛达成的北美联合商业化协议预计将导致其营收在 2022 年及以后大幅增长。事实上，华尔街认为该疫苗在未来两年内北美的销售额可能会超过 4 亿美元。</blockquote> While this experimental vaccine still has to undergo clinical testing in the U.S., as well as a regulatory review in Canada, before Ocugen can start earning revenue from it, the vaccine does appear to workfairly wellbased on its clinical trial data in India. As such, there is a solid basis to believe that this vaccine will eventually be approved in the U.S. and Canada.<blockquote>虽然这种实验性疫苗仍需在美国进行临床试验，以及在加拿大进行监管审查，但在Ocugen开始从中获得收入之前，根据其在印度的临床试验数据，该疫苗似乎效果相当好。因此，有坚实的基础相信这种疫苗最终将在美国和加拿大获得批准。</blockquote> Why is Ocugen's stock a strong buy this month? Ocugen and its partner Bharat Biotech are expecting to receive word on the vaccine's emergency use listing (EUL) application from the World Health Organization (WHO) soon. The WHO has repeatedly asked Bharat Biotech for additional data prior to approving an EUL for Covaxin, leading to a lengthy delay for this key regulatory nod. But a green light could come as soon as Nov. 3, when the WHO's technical advisory group overseeing vaccine EULs meets again.<blockquote>为什么 Ocugen 的股票本月值得强力买入？Ocugen 及其合作伙伴 Bharat Biotech 预计很快将收到世界卫生组织 (WHO) 关于该疫苗紧急使用清单 (EUL) 申请的消息。世卫组织在批准科瓦克辛的EUL之前多次要求Bharat Biotech提供更多数据，导致这一关键监管点头被长时间拖延。但最早可能在 11 月 3 日到来，届时世卫组织负责监督疫苗 EUL 的技术咨询小组将再次开会。</blockquote> Although Ocugen will not financially benefit from a WHO EUL due to the nature of its co-commercialization agreement with Bharat Biotech, it would be huge step in the right direction for the experimental vaccine. The biotech's stock, in turn, will likely continue to march higher in response to a positive EUL decision this month.<blockquote>尽管由于与Bharat Biotech的联合商业化协议的性质，Ocugen不会从世卫组织EUL中获得经济利益，但这将是实验性疫苗朝着正确方向迈出的一大步。反过来，由于本月 EUL 的积极决定，该生物技术公司的股价可能会继续走高。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Biotech Stocks to Buy in November<blockquote>11 月最值得买入的 2 只生物技术股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Biotech Stocks to Buy in November<blockquote>11 月最值得买入的 2 只生物技术股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-11-02 11:15\n\n</h4>\n</header>\n<article>\nBiotech stocks appear to be poised for a strong showing in November for a host of reasons. First and foremost, the industry's biggest headwind this year -- drug pricing reform -- was conspicuously left out of the social spending bill recently released by the White House. Second, the latest earnings reports from top big pharma companies like&nbsp;Merck&nbsp;have been&nbsp;better than expectedso far. Lastly, scores of drugmakers are slated to release key clinical and regulatory updates this month.<blockquote>由于多种原因，生物技术股似乎有望在 11 月份出现强劲表现。首先也是最重要的是，该行业今年最大的阻力——药品定价改革——明显被排除在白宫最近发布的社会支出法案之外。其次，顶级大型制药公司的最新收益报告，例如默克到目前为止比预期要好。最后，数十家制药商将于本月发布关键的临床和监管更新。</blockquote> Which&nbsp;biotech stocks&nbsp;could be the belles of the ball in November?Bionano Genomics(NASDAQ:BNGO)and&nbsp;Ocugen(NASDAQ:OCGN)are two names that growth-oriented investors should definitely have on the radars this month. Here's why.<blockquote>哪些生物科技股可能是 11 月份的亮点？生物纳米基因组学（纳斯达克代码：BNGO）和奥库根（纳斯达克股票代码：OCGN）是成长型投资者本月绝对应该关注的两个名字。原因如下。</blockquote> Bionano Genomics: Time to buy this fallen angel<blockquote>Bionano Genomics：是时候购买这个堕落天使了</blockquote> Personalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.<blockquote>个性化医疗是生物技术研究的圣杯。尽管随着免疫疗法的出现，癌症治疗取得了许多突破，但该领域的临床成功通常以低至30%的缓解率为特征。研究人员认为，这些极低的应答率源于特定患者群体中核酸和整个染色体水平上的突变类型差异。实际上，癌症并不是一种铁板一块的疾病，因此不可能开发出一种放之四海而皆准的疗法。</blockquote> To boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.<blockquote>为了提高这些新型抗癌治疗的功效，研究人员需要在个体水平上准确了解恶性肿瘤的遗传结构。这就是像 Bionano Genomics 这样的公司发挥作用的地方。Bionano Genomicssportsa 基于非测序的光学测绘技术，称为 Saphyr 系统。Saphyr系统旨在快速表征极长的基因组DNA链。</blockquote> What's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.<blockquote>此外，该生物技术公司最近收购了领先的基因组数据分析软件公司 BioDiscovery。这项具有里程碑意义的收购可能会成为公司及其股东改变游戏规则的业务发展举措。简而言之，BioDiscovery 的 NXClinical 变异分析软件解决方案与 Saphyr 系统相结合，有可能加速光学基因组作图的普及。此外，这个潜在的一流平台最终可能会在未来几年内占据这个数十亿美元市场的巨大份额。</blockquote> Why should investors buy this stock in November? Bionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.<blockquote>为什么投资者应该在11月购买这只股票？Bionano 定于 11 月 4 日公布第三季度收益。虽然生物技术公司第三季度的收入数据不太可能引人注目，但投资者应该更多地了解这项关键收购的长期影响。因此，Bionano 遭受重创的股票在经历了八个月的低迷后可能最终开始显示出一些生命迹象。强调这一点的是，这家生物技术公司的股价目前相对于 52 周高点下跌了 67%。反过来，激进的投资者可能希望在即将发布的收益报告之前买入一些股票。</blockquote> Ocugen: An underappreciated COVID-19 vaccine stock<blockquote>Ocugen：被低估的 COVID-19 疫苗股票</blockquote> Thanks to its popularity onsocial media, Ocugen's shares have jumped by an astounding 547% so far this year. The biotech's appeal to the social media crowd isn't without reason, however. Ocugen's North American co-commercialization agreement with India's Bharat Biotech for the COVID-19 vaccine Covaxin is expected to lead to a monstrous rise in its top line in 2022 and beyond. Wall Street, in fact, thinks the vaccine's North American sales may top $400 million within the next two years.<blockquote>由于其在社交媒体上的受欢迎程度，Ocugen 的股价今年迄今已上涨了 547%，令人震惊。然而，生物技术对社交媒体人群的吸引力并非没有原因。Ocugen 与印度 Bharat Biotech 就 COVID-19 疫苗科瓦克辛达成的北美联合商业化协议预计将导致其营收在 2022 年及以后大幅增长。事实上，华尔街认为该疫苗在未来两年内北美的销售额可能会超过 4 亿美元。</blockquote> While this experimental vaccine still has to undergo clinical testing in the U.S., as well as a regulatory review in Canada, before Ocugen can start earning revenue from it, the vaccine does appear to workfairly wellbased on its clinical trial data in India. As such, there is a solid basis to believe that this vaccine will eventually be approved in the U.S. and Canada.<blockquote>虽然这种实验性疫苗仍需在美国进行临床试验，以及在加拿大进行监管审查，但在Ocugen开始从中获得收入之前，根据其在印度的临床试验数据，该疫苗似乎效果相当好。因此，有坚实的基础相信这种疫苗最终将在美国和加拿大获得批准。</blockquote> Why is Ocugen's stock a strong buy this month? Ocugen and its partner Bharat Biotech are expecting to receive word on the vaccine's emergency use listing (EUL) application from the World Health Organization (WHO) soon. The WHO has repeatedly asked Bharat Biotech for additional data prior to approving an EUL for Covaxin, leading to a lengthy delay for this key regulatory nod. But a green light could come as soon as Nov. 3, when the WHO's technical advisory group overseeing vaccine EULs meets again.<blockquote>为什么 Ocugen 的股票本月值得强力买入？Ocugen 及其合作伙伴 Bharat Biotech 预计很快将收到世界卫生组织 (WHO) 关于该疫苗紧急使用清单 (EUL) 申请的消息。世卫组织在批准科瓦克辛的EUL之前多次要求Bharat Biotech提供更多数据，导致这一关键监管点头被长时间拖延。但最早可能在 11 月 3 日到来，届时世卫组织负责监督疫苗 EUL 的技术咨询小组将再次开会。</blockquote> Although Ocugen will not financially benefit from a WHO EUL due to the nature of its co-commercialization agreement with Bharat Biotech, it would be huge step in the right direction for the experimental vaccine. The biotech's stock, in turn, will likely continue to march higher in response to a positive EUL decision this month.<blockquote>尽管由于与Bharat Biotech的联合商业化协议的性质，Ocugen不会从世卫组织EUL中获得经济利益，但这将是实验性疫苗朝着正确方向迈出的一大步。反过来，由于本月 EUL 的积极决定，该生物技术公司的股价可能会继续走高。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/11/01/2-best-biotech-stocks-to-buy-in-november/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","BNGO":"Bionano Genomics"},"source_url":"https://www.fool.com/investing/2021/11/01/2-best-biotech-stocks-to-buy-in-november/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135028228","content_text":"Biotech stocks appear to be poised for a strong showing in November for a host of reasons. First and foremost, the industry's biggest headwind this year -- drug pricing reform -- was conspicuously left out of the social spending bill recently released by the White House. Second, the latest earnings reports from top big pharma companies like Merck have been better than expectedso far. Lastly, scores of drugmakers are slated to release key clinical and regulatory updates this month.\nWhich biotech stocks could be the belles of the ball in November?Bionano Genomics(NASDAQ:BNGO)and Ocugen(NASDAQ:OCGN)are two names that growth-oriented investors should definitely have on the radars this month. Here's why.\nBionano Genomics: Time to buy this fallen angel\nPersonalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.\nTo boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.\nWhat's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.\nWhy should investors buy this stock in November? Bionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.\nOcugen: An underappreciated COVID-19 vaccine stock\nThanks to its popularity onsocial media, Ocugen's shares have jumped by an astounding 547% so far this year. The biotech's appeal to the social media crowd isn't without reason, however. Ocugen's North American co-commercialization agreement with India's Bharat Biotech for the COVID-19 vaccine Covaxin is expected to lead to a monstrous rise in its top line in 2022 and beyond. Wall Street, in fact, thinks the vaccine's North American sales may top $400 million within the next two years.\nWhile this experimental vaccine still has to undergo clinical testing in the U.S., as well as a regulatory review in Canada, before Ocugen can start earning revenue from it, the vaccine does appear to workfairly wellbased on its clinical trial data in India. As such, there is a solid basis to believe that this vaccine will eventually be approved in the U.S. and Canada.\nWhy is Ocugen's stock a strong buy this month? Ocugen and its partner Bharat Biotech are expecting to receive word on the vaccine's emergency use listing (EUL) application from the World Health Organization (WHO) soon. The WHO has repeatedly asked Bharat Biotech for additional data prior to approving an EUL for Covaxin, leading to a lengthy delay for this key regulatory nod. But a green light could come as soon as Nov. 3, when the WHO's technical advisory group overseeing vaccine EULs meets again.\nAlthough Ocugen will not financially benefit from a WHO EUL due to the nature of its co-commercialization agreement with Bharat Biotech, it would be huge step in the right direction for the experimental vaccine. The biotech's stock, in turn, will likely continue to march higher in response to a positive EUL decision this month.","news_type":1,"symbols_score_info":{"BNGO":0.9,"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2677,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":31,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/841072224"}